Micro-cap Losers: Curis, (NASDAQ:CRIS), WidePoint Corporation (NYSEMKT:WYY), Sigma Designs (NASDAQ:SIGM), Prana Biotechnology Limited (NASDAQ:PRAN)

Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Curis, Inc. (NASDAQ:CRIS), shares after opening at $2.70 moved to $2.71 on last trade day and at the end of the day closed at $2.51. Company price to sales ratio in past twelve months was calculated as 14.38 and price to cash ratio as 3.71. Curis, Inc. (NASDAQ:CRIS), showed a negative weekly performance of 10.04%.

On March 19, 2014, WidePoint Corporation (NYSEMKT:WYY), a leading provider of enterprise-wide Managed Mobility Solutions featuring mobile telecommunications management, cybersecurity, identity and data assurance, and consulting solutions deliverable in a secured environment, announced that it will be reporting its full year 2013 financial results on March 31, 2014, after the close of the market. WidePoint Corporation (NYSEMKT:WYY), shares fell 1.40% in last trading session and ended the day on $8.50. WidePoint Corporation (NYSEMKT:WYY), return on equity ratio is recorded as 5.00% and its return on assets is 3.20%. WidePoint Corporation (NYSEMKT:WYY), yearly performance is 150.00%.

On April 9, 2014, Sigma Designs Inc (NASDAQ:SIGM), reported fourth-quarter net income of $1.3 million or $0.04 per share, compared to net loss of $35.2 million or $1.04 per share in the comparable quarter last year. Sigma Designs Inc (NASDAQ:SIGM), shares moved down 8.54% in last trading session and was closed at $4.39, while trading in range of $ 4.31 – 4.62. Sigma Designs Inc (NASDAQ:SIGM), year to date (YTD) performance is -6.99%.

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) announces issue of ordinary shares to carry out its business proceeds. The firm has decided to issue 59.17 million ordinary shares for a consideration of a $16.38 million. The amount generated will be used to carry out the research programs. It will also fulfill the need of working capital and will support the current clinical development Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), weekly performance is -18.60%. On last trading day company shares ended up $1.97. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), distance from 50-day simple moving average (SMA50) is -77.88%. Analysts mean target Price for the company is $4.00.